Literature DB >> 23974650

Synergy between the pharmacological chaperone 1-deoxygalactonojirimycin and agalsidase alpha in cultured fibroblasts from patients with Fabry disease.

Antonio Pisani1, Caterina Porto, Generoso Andria, Giancarlo Parenti.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23974650     DOI： 10.1007/s10545-013-9641-z

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN： 0141-8955            Impact factor:   4.982


× No keyword cloud information.
  2 in total

1.  Synergy between the pharmacological chaperone 1-deoxygalactonojirimycin and the human recombinant alpha-galactosidase A in cultured fibroblasts from patients with Fabry disease.

Authors:  Caterina Porto; Antonio Pisani; Margherita Rosa; Emma Acampora; Valeria Avolio; Maria Rosaria Tuzzi; Bianca Visciano; Cristina Gagliardo; Serena Materazzi; Giancarlo la Marca; Generoso Andria; Giancarlo Parenti
Journal:  J Inherit Metab Dis       Date:  2011-12-21       Impact factor: 4.982

2.  The pharmacological chaperone N-butyldeoxynojirimycin enhances enzyme replacement therapy in Pompe disease fibroblasts.

Authors:  Caterina Porto; Monica Cardone; Federica Fontana; Barbara Rossi; Maria Rosaria Tuzzi; Antonietta Tarallo; Maria Vittoria Barone; Generoso Andria; Giancarlo Parenti
Journal:  Mol Ther       Date:  2009-03-17       Impact factor: 11.454
  2 in total
  2 in total

Review 1.  Pharmacological Chaperone Therapy: Preclinical Development, Clinical Translation, and Prospects for the Treatment of Lysosomal Storage Disorders.

Authors:  Giancarlo Parenti; Generoso Andria; Kenneth J Valenzano
Journal:  Mol Ther       Date:  2015-04-16       Impact factor: 11.454

Review 2.  Fabry Disease: Molecular Basis, Pathophysiology, Diagnostics and Potential Therapeutic Directions.

Authors:  Ken Kok; Kimberley C Zwiers; Rolf G Boot; Hermen S Overkleeft; Johannes M F G Aerts; Marta Artola
Journal:  Biomolecules       Date:  2021-02-12
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.